Chen Wei-Hong, Liu Hen-Yu, Lo Wen-Cheng, Wu Shinn-Chih, Chi Chau-Hwa, Chang Hsueh-Yuan, Hsiao Shih-Hsiang, Wu Chih-Hsiung, Chiu Wen-Ta, Chen Bao-Ji, Deng Win-Ping
Stem Cell Research Center, Taipei Medical University, Taipei, Taiwan, ROC.
Biomaterials. 2009 Oct;30(29):5523-33. doi: 10.1016/j.biomaterials.2009.07.019. Epub 2009 Jul 30.
An ex vivo degenerative intervertebral disc (IVD) organ culture system was established for the screening of disc regeneration agents. Its application was demonstrated by a stem cell and growth factor-based therapeutic approach for the amelioration of IVD. An ex vivo culture system using chymopapain to partially digest nucleus proposus tissue was established to mimic human IVD degeneration. This system was then used for the evaluation of different therapeutic regimens including: mesenchymal stem cell derived from eGFP-transgenic porcine (MSC-GFP), platelet-rich plasma (PRP) and MSC-GFP/PRP combined treatment, and confirmed in in vivo animal model. Chondrogenic-specific gene products including Col II and aggrecan were found upregulated and chondrogenic matrix deposition increased, as evident by sustained fluorescent signals over 4 weeks, in the MSC-GFP implanted group. Previously, we demonstrated in vitro stage-specific chondrogenesis of MSC by chondrocytic commitment. These same molecules upregulated for chondrogenesis were also observed in MSC-GFP group. PRP that has been shown to promote nucleus pulposus (NP) regeneration also resulted in significant increased levels of mRNA involved in chondrogenesis and matrices accumulation. The ex vivo IVD regeneration results were repeated and supported by in vivo porcine degenerative system. Moreover, the disc height index (DHI) was significantly increased in both in vivo MSC-GFP and PRP regeneration groups. Unexpectedly, the MSC-GFP/PRP combined therapy demonstrated an inclination towards osteogenesis in ex vivo system. The ex vivo degenerative IVD culture system described in this study could serve as an alternative and more accessible model over large animal model. This system also provides a high-throughput platform for screening therapeutic agents for IVD regeneration.
建立了一种用于筛选椎间盘再生剂的体外退变椎间盘(IVD)器官培养系统。通过基于干细胞和生长因子的治疗方法改善IVD,证明了该系统的应用。建立了一种使用木瓜凝乳蛋白酶部分消化髓核组织的体外培养系统,以模拟人类IVD退变。然后将该系统用于评估不同的治疗方案,包括:源自eGFP转基因猪的间充质干细胞(MSC-GFP)、富血小板血浆(PRP)以及MSC-GFP/PRP联合治疗,并在体内动物模型中得到证实。在植入MSC-GFP的组中,发现软骨特异性基因产物包括II型胶原和聚集蛋白聚糖上调,软骨基质沉积增加,这在4周内持续的荧光信号中很明显。此前,我们通过软骨细胞定向分化证明了MSC在体外阶段特异性软骨生成。在MSC-GFP组中也观察到了这些相同的上调用于软骨生成的分子。已证明能促进髓核(NP)再生的PRP也导致软骨生成相关mRNA水平显著增加和基质积累。体外IVD再生结果在体内猪退变系统中得到重复和支持。此外,体内MSC-GFP和PRP再生组的椎间盘高度指数(DHI)均显著增加。出乎意料的是,在体外系统中,MSC-GFP/PRP联合治疗显示出成骨倾向。本研究中描述的体外退变IVD培养系统可作为大型动物模型的替代且更易获得的模型。该系统还为筛选IVD再生治疗剂提供了一个高通量平台。